百济神州:商业化产品多项新增适应症被纳入2024国家医保药品目录

美港电讯
28 Nov 2024

【百济神州:商业化产品多项新增适应症被纳入2024国家医保药品目录】金十数据11月28日讯,百济神州(06160.HK)宣布,公司自主研发的抗PD-1抗体百泽安(替雷利珠单抗注射液)、BTK抑制剂百悦泽(泽布替尼胶囊)分别新增三项适应症和一项适应症被纳入新版国家医保药品目录;合作引进产品百拓维(注射用戈舍瑞林微球)新增一项适应症被纳入国家医保药品目录,凯洛斯(注射用卡非佐米)成功续约。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10